GSK3B and liver cancer: Generally, WNT signaling activation disrupts the binding of Glycogen synthase kinase 3 beta (GSK3β) to β-catenin to allow the later to translocate to the nucleus and activate target gene transduction, including ZEB1, but several other molecules can modulate this cascade in liver cancer.